Paediatric extensions: a recent article

"Better Medicines for children? What have been the benefits and lessons learned after 5 years of the Paediatric Regulation?", by Grant Strachan (an Associate, Bristows LLP, London), has recently been published in the Bio-Science Law Review, published six times a year by Lawtext. According to the abstract:

"Maintaining the pace of innovation in the life sciences sector is a complex and challenging process for all pharmaceutical companies engaged in research and development. Prior to 2006, there was a lack of suitably authorised medicinal products for paediatric use. To combat this problem the Paediatric Regulation was implemented in order to facilitate the development and accessibility of age-appropriate paediatric medicines. The European Commission has recently published a progress report which provides an in-depth appraisal of the successes and failures of the Paediatric Regulation. The recommendations outlined in this report will shape the development of this important piece of legislation, which is of crucial significance for innovator companies operating in the life sciences sector and to the paediatric population as the ultimate beneficiary of an effective regulatory platform that supports innovation".